Biomarker Analysis in Post-COVID Patients

University Hospital Bonn (UKB)

Status: Completed

Conditions: Post-COVID-19 Syndrome

Treatments: Other: no intervention

Study type: Observational

Funder types: Other

Identifiers

NCT05836428

2

Details and patient eligibility

About

Headache is one of the most common neurological manifestations of COVID-19. However, it is unclear whether chronic headache after the initial diagnosis, is associated with ongoing damage of the central nervous system. We investigate cpost-COVID-19 patients with persistent headache lasting longer than 3 weeks, to hospitalized acute COVID-19 patients with neurological symptoms and to other non-COVID-19 disease-controls. Readout are neurologial and glial biomarkers in CSF.

Full description

Measurements of neuronal and glial markers in CSF were performed on a SIMOA analyzer (Quanterix) using the Neurology 4-Plex A (Nf-L, Tau, GFAP, UCH-L1) kit.

Enrollment: 48 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Diagnosis of COVID, Parkinson's disease, primary headache, Multiples Sclerosis, facial paralysis
• Persistent post-COVID-19 headache after 3 months of infection
• Post COVID-patients without persistent headache
• must be able to perform lumbar puncture

Exclusion criteria

• unknown history of COVID infection
• lumbar puncture not possible

Trial design

48 participants in 2 patient groups

Persistent post-COVID-19 headache

Description:

post-COVID-19 patients with persistent headache

Treatment:

Other: no intervention

controls

Description:

Mild Neuro-COVID-19 patients without persistent headache and other neurological diseases

Treatment:

Other: no intervention